Hillsdale Investment Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Hillsdale Investment Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-400	Closed	-$6.29K	–	718
2024 Q1	$6.29K	Hold	400	–	–	﹤0.01%	535
2023 Q4	$6.45K	Hold	400	–	–	﹤0.01%	485
2023 Q3	$5.09K	Sell	400 -180	-31%	-$2.48K	﹤0.01%	509
2023 Q2	$8.17K	Sell	580 -252,620	-100%	-$3.61M	﹤0.01%	444
2023 Q1	$3.91M	Sell	253,200 -75,000	-23%	-$1.25M	0.33%	116
2022 Q4	$5.38M	Buy	328,200 +2,800	+0.9%	+$45.5K	0.45%	58
2022 Q3	$6.02M	Buy	+325,400	New	+$5.11M	0.54%	42

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Hillsdale Investment Management's DCPH Position: Q2 2024 in Review

Hillsdale Investment Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 400 shares — an estimated $6.29K sold.

Hillsdale Investment Management first reported a position in DCPH in Q3 2022 and held it in 7 quarters. The position peaked at $6.02M in Q3 2022. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

Hillsdale Investment Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Hillsdale Investment Management sold 400 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $6.29K.
Hillsdale Investment Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 7 quarters.
Hillsdale Investment Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $6.02M in Q3 2022.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Hillsdale Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.